Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies
ConclusionSingle-agent ofatumumab is a well-tolerated and effective therapeutic approach for treatment-naïve older patients with CLL; it can be safely administered to patients with significant comorbidities and other cancer diagnoses.
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Candida | Chronic Leukemia | Chronic Lymphocytic Leukemia | Clinical Trials | Geriatrics | Leukemia | Pulmonary Thromboembolism | Study | Toxicology